Regeneus, a clinical-stage regenerative medicine company, has announced that it has received a Notice of Intention which shows a European patent granted for Progenza.
Progenza is an allogeneic off-the-shelf stem cell technology platform developed for the treatment of osteoarthritis and other musculoskeletal diseases. It has the potential to be used for other inflammatory diseases that have limited treatment options.
The European patent granted for Progenza is for EP 2 744 892 entitled “Therapeutics using adipose cells and cell secretions” will provide Regeneus with the commercial rights to Progenza in up to 38 European member states of the European Patent Office, including the UK, Germany, France and Italy, until 15 March 2032.
The patent will join corresponding patents already secured in Australia, New Zealand, Japan and the United States of America, providing significant protection of the Company’s commercial rights to the Progenza technology platform in some of the world’s largest regenerative therapy markets. The Company continues to progress additional patent applications for Progenza in other key territories.
Progenza is made from expanded mesenchymal stem cells (MSCs) from human adipose tissue, it contains the bioactive secretions of cells. Progenza cells work by secreting cytokines, growth factors and exosomes that act in concert to reduce inflammation and pain and encourage accelerated healing and repair of damaged or diseased tissue. It is a scalable technology that has demonstrated capability to produce millions of doses of cells from a single donor.